PropertyValue
?:abstract
  • Less than 8 months after establishing a collaboration to develop a vaccine for COVID-19 , Pfizer and BioNTech have declared success An ongoing Phase 3 study of more than 43,500 people showed that the vaccine was more than 90% effective at preventing COVID-19—significantly exceeding the US Food and Drug Administration’s approval requirement that any vaccine be at least 50% effective It’s the first announcement of a successful late-stage trial from hundreds of groups racing to develop a vaccine “This is great news,” says Norbert Pardi, a messenger RNA (mRNA) vaccine scientist at the University of Pennsylvania “We need to see more data, but we definitely have reason to be optimistic ” The news comes amid record-breaking numbers of daily cases of COVID-19 in the US, which has already seen more than 230,000 deaths from the virus But the results carry several important caveats Because the announcement was made in a press [ ]
?:creator
?:journal
  • C&EN_Global_Enterprise
?:license
  • unk
?:publication_isRelatedTo_Disease
?:source
  • WHO
?:title
  • Pfizer, BioNTech say their COVID-19 vaccine is successful in late-stage trial
?:type
?:who_covidence_id
  • #926915
?:year
  • 2020

Metadata

Anon_0  
<http://www.w3.org/1999/02/22-rdf-syntax-ns#type> <http://purl.org/net/provenance/ns#DataItem>
<http://www.w3.org/1999/02/22-rdf-syntax-ns#type> <http://www.w3.org/2004/03/trix/rdfg-1/Graph>
<http://xmlns.com/foaf/0.1/primaryTopic> <https://research.tib.eu/covid-19/entity/gx2vjj2v>
<http://xmlns.com/foaf/0.1/topic> Anon_0
<http://www.ontologydesignpatterns.org/cp/owl/informationrealization.owl#realizes> <https://research.tib.eu/covid-19/data/entity/gx2vjj2v>
<http://purl.org/net/provenance/ns#createdBy>
Anon_1   (more)
expand all